STARPHARMA HLDG.SP.ADR/10 (PQ6A) - Net Assets
Based on the latest financial reports, STARPHARMA HLDG.SP.ADR/10 (PQ6A) has net assets worth €19.00 Million EUR (≈ $22.21 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€25.42 Million ≈ $29.72 Million USD) and total liabilities (€6.42 Million ≈ $7.51 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read STARPHARMA HLDG.SP.ADR/10 (PQ6A) financial obligations for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €19.00 Million |
| % of Total Assets | 74.73% |
| Annual Growth Rate | -26.77% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 5.49 |
STARPHARMA HLDG.SP.ADR/10 - Net Assets Trend (2022–2025)
This chart illustrates how STARPHARMA HLDG.SP.ADR/10's net assets have evolved over time, based on quarterly financial data. Also explore PQ6A total asset value for the complete picture of this company's asset base.
Annual Net Assets for STARPHARMA HLDG.SP.ADR/10 (2022–2025)
The table below shows the annual net assets of STARPHARMA HLDG.SP.ADR/10 from 2022 to 2025. For live valuation and market cap data, see STARPHARMA HLDG.SP.ADR/10 (PQ6A) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | €19.00 Million ≈ $22.21 Million |
-32.43% |
| 2024-06-30 | €28.12 Million ≈ $32.87 Million |
-19.24% |
| 2023-06-30 | €34.81 Million ≈ $40.70 Million |
-28.06% |
| 2022-06-30 | €48.39 Million ≈ $56.58 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to STARPHARMA HLDG.SP.ADR/10's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3379200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €271.35 Million | 1428.31% |
| Total Equity | €19.00 Million | 100.00% |
STARPHARMA HLDG.SP.ADR/10 Competitors by Market Cap
The table below lists competitors of STARPHARMA HLDG.SP.ADR/10 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Se Gyung Hi Tech Co.Ltd
KQ:148150
|
$99.16 Million |
|
Maeil Holdings Co. Ltd
KQ:005990
|
$99.23 Million |
|
Richmond International Travel & Tours Co Ltd
TWO:2743
|
$99.26 Million |
|
Kencana Agri Limited
F:KEBA
|
$99.31 Million |
|
Jasa Armada Indonesia Tbk PT
JK:IPCM
|
$99.09 Million |
|
Sree Rayalaseema Hi-Strength Hypo Limited
NSE:SRHHYPOLTD
|
$99.09 Million |
|
IFB Agro Industries Limited
NSE:IFBAGRO
|
$99.09 Million |
|
WI Co. Ltd.
KQ:073570
|
$99.06 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in STARPHARMA HLDG.SP.ADR/10's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 28,116,000 to 18,998,000, a change of -9,118,000 (-32.4%).
- Net loss of 9,990,000 reduced equity.
- Other factors increased equity by 872,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-9.99 Million | -52.58% |
| Other Changes | €872.00K | +4.59% |
| Total Change | €- | -32.43% |
Book Value vs Market Value Analysis
This analysis compares STARPHARMA HLDG.SP.ADR/10's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 96.86x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 37.14x to 96.86x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-06-30 | €0.12 | €4.40 | x |
| 2023-06-30 | €0.08 | €4.40 | x |
| 2024-06-30 | €0.07 | €4.40 | x |
| 2025-06-30 | €0.05 | €4.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently STARPHARMA HLDG.SP.ADR/10 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -52.58%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -203.38%
- • Asset Turnover: 0.19x
- • Equity Multiplier: 1.34x
- Recent ROE (-52.58%) is below the historical average (-39.98%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -33.38% | -345.02% | 0.07x | 1.37x | €-20.99 Million |
| 2023 | -44.92% | -532.09% | 0.06x | 1.50x | €-19.12 Million |
| 2024 | -29.04% | -98.50% | 0.23x | 1.31x | €-10.98 Million |
| 2025 | -52.58% | -203.38% | 0.19x | 1.34x | €-11.89 Million |
Industry Comparison
This section compares STARPHARMA HLDG.SP.ADR/10's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $355,224,390
- Average return on equity (ROE) among peers: -60.76%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| STARPHARMA HLDG.SP.ADR/10 (PQ6A) | €19.00 Million | -33.38% | 0.34x | $99.13 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $66.68 Million | -96.62% | 1.57x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $3.94 Million | -301.40% | 1.87x | $161.62 Million |
| Theravance Biopharma Inc (0TB) | $289.79 Million | -81.80% | 0.17x | $823.46 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $230.94 Million | -20.03% | 0.13x | $205.51 Million |
| PreveCeutical Medical Inc (18H) | $-4.49 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $1.36 Billion | -38.77% | 0.36x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $-45.09 Million | 0.00% | 0.00x | $1.14 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $-852.32K | 0.00% | 0.00x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $1.38 Billion | -51.05% | 0.17x | $1.82 Billion |
| BioNTech SE (22UA) | $267.00 Million | -17.98% | 1.45x | $20.05 Billion |
About STARPHARMA HLDG.SP.ADR/10
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company's products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurr… Read more